Conagra Brands Inc vs Twist Bioscience Corp — how do they compare? Conagra Brands Inc trades at $14.79 (market cap $7.14B), while Twist Bioscience Corp trades at $121.77 (market cap $7.72B). The key difference: Conagra Brands Inc and Twist Bioscience Corp are close in size by market cap, and Conagra Brands Inc pays a 8.2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CAG | TWST | |
|---|---|---|
Market Cap | $7.14B | $7.72B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $124.88 |
52-Week Low | $12.58 | $24.16 |
Enterprise Value | $14.20B | $7.65B |
Dividend Yield | 8.2% | — |
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.78, down 2.18% today, with a bearish technical signal and neutral oscillators. The company reported a net income margin of -16.99% for 2026, with revenue declining to $11.3B, while 2025 showed stronger profitability. Recent corporate actions include a dividend cut to $0.18 and leadership changes under CEO John Brase, aiming to streamline operations and reduce debt.
The outlook is mixed: low valuation metrics (P/E 10.06, P/S 0.63) offer downside support, but weak growth and margin pressures pose risks. Analyst consensus is cautious with a $13.67 price target, and institutional sentiment is divided amid ongoing turnaround efforts. Key risks include consumer pushback on pricing and execution challenges under new management.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →